Mukhopadhyay et al. [281] discovered synthetic lethal genes in KRAS/LKB1 co-mutated NSCLC that bolster efficacy of KRASG12C inhibitors, implicating components of autophagy, Hippo and c-Myc pathways, thus opening avenues for novel therapeutic strategies. This evidence concerns the gene KRAS and non-small cell lung carcinoma.